Health Policy
WHO guidelines, EU directives, and Georgian health governance
Biotech M&A Accelerates: AbbVie’s Apogee Deal Signals Return of Major Acquisitions
AbbVie's acquisition of Apogee Therapeutics marks a significant return to biotech M&A activity after an extended sector slowdown. Recent positive…
Editor's Top Picks
Why Women Doctors Drop Out: A Systematic Review Reveals Critical Gaps in Medical Training
A systematic review of global research on women physicians reveals persistent barriers to career advancement—from work-life balance conflicts and mentorship…
Submit Your Paper →
More form Health Policy
Nobody Approves a Supplement Before It Is Sold
Supplements are foods, not medicines. No regulator anywhere approves them before sale. What that means…
Eli Lilly’s Obesity Drug Access: What We Know About FDA Approval Pathways
Regulatory pathways and corporate strategy shape early access to obesity drug candidates. Pharmaceutical acquisitions in…
Biotech Industry Faces Political Uncertainty and AI Profitability Questions at BIO 2026
Biotech executives at BIO 2026 confronted mounting concerns over Chinese competition, the uncertain profitability of…
The EU Nutrient Reference Value (NRV): What 1,000% on a Label Really Means
NRV percentages confuse more consumers than any other label element: 1,000% sounds alarming until you…
The Georgian Supplement Market: What the Law Requires — and What Compliance Reviews Find
Georgian law aligns supplement rules with the EU framework on paper. PHIG's documentation of the…